Search

Cystoid macular oedema following retinal detachment surgery

There are limited studies examining the incidence and risk factors for postoperative cystoid macular oedema (CMO) following rhegmatogenous retinal detachment (RRD) repair. Postoperative CMO is thought to be due to pro-inflammatory state, where numerous cytokines lead to tight junction dysfunction,...

Long-term treatment for diabetic macular oedema

The authors set out to characterise anti-VEGF treatment patterns and long-term outcomes in patients with diabetic macular oedema. A retrospective analysis of over 190 thousand patients on the Intelligent Research in Sight registry was performed. Of these, 1236 eyes have...

Bromfenac versus betamethasone in diabetic macular oedema

This is a randomised, prospective, single-centre trial in patients diagnosed with diabetic macular oedema (DMO) with central subfield thickness (CST) of 250-500µm, who refused anti-VEGF treatment. Nineteen eyes of 19 patients were randomised to bromfenac (BF) or betamethasone (BM) drops,...

Outcomes of treat & extend ranibizumab in diabetic macular oedema

This study retrospectively evaluated 118 eyes of 87 patients who received ranibizumab in a treat and extend regimen for diabetic macular oedema (DMO). Data were collected for patients under follow-up for 24 months. After 24 months, patients gained a mean...

Steroid treatment for pseudophakic cystoid macular oedema

The authors present a retrospective comparison of 45 eyes of 41 patients treated with 2mg intravitreal triamcinolone (IVT group) and 50 eyes of 42 patients treated with 40mg sub-Tenons triamcinolone (STT group) for pseudophakic cystoid macular oedema (CMO). The visual...

Intravitreal dexamethasone implant for diabetic macular oedema

The authors report on the three-year outcomes of the Ozurdex Dexamethasone (DEX) intravitreal implant multi-centre trial for the treatment of diabetic macular oedema (DME). Patients with DME (best-corrected vision of 20/50 to 20/200 and central retinal thickness of ≥300µm) were...

Cystoid macular oedema following cataract surgery

This review covers the history, incidence, diagnosis, risk factors, pathophysiology and medical management of postoperative macular oedema (PCMO), with a particular emphasis on key contemporary studies and novel observations. The authors revisit the incidence of well-established risk factors including intraoperative...

A novel presentation of optic disc oedema with syphilis

Optic disc oedema (ODE) due to syphilis without visual compromise has been primarily attributed to papilloedema from raised intracranial pressure or optic perineuritis from optic nerve sheath inflammation. These terms were proposed before magnetic resonance imaging (MRI) was largely available....

Inner nuclear layer of the retina showing increase in thickness in diabetic macular oedema

Diabetic retinopathy is one of the leading causes of blindness in the developed world. With optical coherence tomography (OCT), it has become possible to image the retina in vivo and to measure retinal oedema by measuring retinal thickness (RT) with...

High dose (2.5mg) bevacizumab for postradiation cystoid macular oedema

The authors present a retrospective, interventional case series investigating the efficacy of high dose (2.5mg/0.1ml) intravitreal bevacizumab in the treatment of persistent postradiation (Iodine-125 plaque brachytherapy for uveal melanoma) cystoid macular oedema (CME). Persistent CME was defined as increased or...